C4 Therapeutics, Inc.

C4 Therapeutics, Inc. held its Annual Meeting of Stockholders on June 24, 2026. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors. They also approved the non-binding advisory vote on executive compensation and ratified KPMG LLP as the independent registered public accounting firm for 2026. Additionally, an amendment to the Company's 2020 Stock Option and Incentive Plan was approved, modifying the evergreen provision to include outstanding pre-funded warrants.

C4 Therapeutics, Inc. announced the presentation of updated Phase 1 data for its investigational drug cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association (EHA) 2026 Congress. The data, with a cutoff of February 27, 2026, showed a 53% overall response rate (ORR) at the recommended Phase 2 dose (RP2D) of 100 µg, with responses deepening over time and some achieving stringent complete response (sCR) and minimal residual disease (MRD) negativity. The combination was generally well-tolerated. The company is advancing cemsidomide through further clinical trials, including the Phase 2 MOMENTUM trial in 4L+ MM and a Phase 1b trial with elranatamab, and is also exploring a new discovery strategy in INN diseases.

C4 Therapeutics presented positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, in relapsed/refractory multiple myeloma (RRMM) at EHA 2026. At the 100 µg Recommended Phase 2 Dose, cemsidomide achieved a 53% Overall Response Rate, including complete responses and minimal residual disease negative status. The drug demonstrated a differentiated safety profile and was well tolerated, supporting its potential as a foundational therapy for RRMM. The company plans further development, including a Phase 2 trial and a combination study with elranatamab.

C4 Therapeutics, Inc. announced that its management will participate in three upcoming healthcare conferences. These include a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026, and a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. Additionally, management will hold 1x1 meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. Live webcasts and archived replays will be available on the company's investor relations website.

C4 Therapeutics announced that its Board's Organization, Leadership and Compensation Committee approved an inducement grant of non-qualified stock options for 85,480 shares to a new employee on May 18, 2026. This grant serves as a material inducement for the individual's employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing stock price on the grant date and will vest over four years, with 25% vesting after the first year and the remainder monthly thereafter, contingent on continued employment.

C4 Therapeutics announced a change in its principal accounting officer role. Mark Mossler will no longer serve as Chief Accounting Officer, effective May 15, 2026, a departure not due to any disagreements. Kendra R. Adams, the company's Chief Financial Officer, Head of Corporate Affairs, and Treasurer, has been designated as the new principal accounting officer, effective the same date. Ms. Adams will not receive additional compensation for this expanded role.

C4 Therapeutics reported a net loss of $25.1 million for the first quarter of 2026, an improvement from the $26.3 million net loss in the same period last year. Revenue from collaboration agreements was $6.15 million, down from $7.24 million year-over-year. The company ended the quarter with $268.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months.

C4 Therapeutics reported its first quarter 2026 financial results, with revenue decreasing to $6.2 million and net loss improving to $25.1 million. The company highlighted significant progress in its clinical pipeline, including the initiation of two new trials for cemsidomide in multiple myeloma and an expanded partnership with Roche for degrader-antibody conjugates, which included a $20 million upfront payment. C4 Therapeutics maintains a strong balance sheet with a cash runway projected to last until the end of 2028.

C4 Therapeutics reported Q1 2026 financial results and significant business advancements. The company progressed plans for cemsidomide as a potential foundational treatment for multiple myeloma, with ongoing enrollment in Phase 2 MOMENTUM and Phase 1b trials, and a new Phase 1b trial expected in H1 2027. C4T also expanded its partnership with Roche through a new collaboration focused on degrader antibody conjugates, receiving a $20 million upfront payment. Financially, the company reported $6.2 million in revenue and a net loss of $25.1 million, with a strong cash position of $268.3 million providing a runway to the end of 2028.

C4 Therapeutics highlighted significant progress in its targeted protein degradation mission, advancing cemsidomide for multiple myeloma into Phase 2 and Phase 1b trials, including a collaboration with Pfizer. The company also implemented a new discovery strategy focused on inflammation, neuroinflammation, and neurodegeneration, and strengthened its balance sheet by raising $125 million, extending its cash runway to the end of 2028. The company also announced its 2026 Annual Meeting of Stockholders for June 24, 2026, to elect directors, approve executive compensation, ratify auditors, and amend its 2020 Stock Option and Incentive Plan.